We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts expect Viatris (VTRS - Free Report) to post quarterly earnings of $0.52 per share in its upcoming report, which indicates a year-over-year increase of 4%. Revenues are expected to be $3.35 billion, up 3.1% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Viatris metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Net Sales- Developed Markets' will reach $1.96 billion. The estimate suggests a change of +3.4% year over year.
Analysts forecast 'Net Sales- Greater China' to reach $588.83 million. The estimate indicates a change of +6% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- JANZ' will reach $256.07 million. The estimate indicates a year-over-year change of -7.3%.
Analysts expect 'Net Sales- Emerging Markets' to come in at $570.75 million. The estimate suggests a change of +9.8% year over year.
The consensus estimate for 'Net Sales- Developed Markets- Brands' stands at $1.05 billion. The estimate suggests a change of +3.3% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Other revenues' of $10.55 million. The estimate indicates a year-over-year change of -5%.
The average prediction of analysts places 'Net Sales- JANZ- Brands' at $125.94 million. The estimate suggests a change of -11.2% year over year.
Based on the collective assessment of analysts, 'Net Sales- JANZ- Generics' should arrive at $130.13 million. The estimate suggests a change of -3.1% year over year.
Analysts predict that the 'Net Sales- Emerging Markets- Brands' will reach $436.20 million. The estimate suggests a change of +8.4% year over year.
The combined assessment of analysts suggests that 'Net Sales- Emerging Markets- Generics' will likely reach $134.55 million. The estimate indicates a change of +14.6% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Total Net Sales' should come in at $3.37 billion. The estimate points to a change of +4% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Developed Markets- Generics' reaching $902.92 million. The estimate indicates a year-over-year change of +3.6%.
Over the past month, shares of Viatris have returned +17.9% versus the Zacks S&P 500 composite's +10.3% change. Currently, VTRS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPS
Wall Street analysts expect Viatris (VTRS - Free Report) to post quarterly earnings of $0.52 per share in its upcoming report, which indicates a year-over-year increase of 4%. Revenues are expected to be $3.35 billion, up 3.1% from the year-ago quarter.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Viatris metrics that Wall Street analysts commonly model and monitor.
The consensus among analysts is that 'Net Sales- Developed Markets' will reach $1.96 billion. The estimate suggests a change of +3.4% year over year.
Analysts forecast 'Net Sales- Greater China' to reach $588.83 million. The estimate indicates a change of +6% from the prior-year quarter.
It is projected by analysts that the 'Net Sales- JANZ' will reach $256.07 million. The estimate indicates a year-over-year change of -7.3%.
Analysts expect 'Net Sales- Emerging Markets' to come in at $570.75 million. The estimate suggests a change of +9.8% year over year.
The consensus estimate for 'Net Sales- Developed Markets- Brands' stands at $1.05 billion. The estimate suggests a change of +3.3% year over year.
The collective assessment of analysts points to an estimated 'Revenues- Other revenues' of $10.55 million. The estimate indicates a year-over-year change of -5%.
The average prediction of analysts places 'Net Sales- JANZ- Brands' at $125.94 million. The estimate suggests a change of -11.2% year over year.
Based on the collective assessment of analysts, 'Net Sales- JANZ- Generics' should arrive at $130.13 million. The estimate suggests a change of -3.1% year over year.
Analysts predict that the 'Net Sales- Emerging Markets- Brands' will reach $436.20 million. The estimate suggests a change of +8.4% year over year.
The combined assessment of analysts suggests that 'Net Sales- Emerging Markets- Generics' will likely reach $134.55 million. The estimate indicates a change of +14.6% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Total Net Sales' should come in at $3.37 billion. The estimate points to a change of +4% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Developed Markets- Generics' reaching $902.92 million. The estimate indicates a year-over-year change of +3.6%.
View all Key Company Metrics for Viatris here>>>Over the past month, shares of Viatris have returned +17.9% versus the Zacks S&P 500 composite's +10.3% change. Currently, VTRS carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .